Gut microbiome-mediated mechanisms for reducing cholesterol levels: implications for ameliorating cardiovascular disease

Trends Microbiol. 2023 Jan;31(1):76-91. doi: 10.1016/j.tim.2022.08.003. Epub 2022 Aug 22.

Abstract

Cardiovascular disease (CVD) is a health problem worldwide, and elevated cholesterol levels are a key risk factor for the disease. Dysbiotic gut microbiota has been shown to be associated with CVD development. However, the beneficial effects of healthy microbiota in decreasing cholesterol levels have not been summarized. Herein, we begin by discussing the potential mechanisms by which the gut microbiota reduces cholesterol levels. We further sketch the application of probiotics from the genera Lactobacillus and Bifidobacterium in reducing cholesterol levels in clinical studies. Finally, we present the cholesterol-lowering function of beneficial commensal microbes, such as Akkermansia and Bacteroides spp., as these microbes have potential to be the next-generation probiotics (NGPs). The information reviewed in this paper will help people to understand how the gut microbiome might alter cholesterol metabolism and enable the development of NGPs to prevent and treat CVD.

Keywords: bile acids; hypercholesterolemia; live biotherapeutic products; short-chain fatty acids; steroid.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cardiovascular Diseases* / prevention & control
  • Cholesterol / pharmacology
  • Cholesterol / therapeutic use
  • Gastrointestinal Microbiome*
  • Humans
  • Hypercholesterolemia* / drug therapy
  • Microbiota*
  • Probiotics* / therapeutic use

Substances

  • Cholesterol